Mizuho analyst Graig Suvannavejh has identified EyePoint, Inc. as his top selection in the small- and mid-cap biotechnology space, highlighting an upcoming clinical-data event that could meaningfully alter the company’s valuation.
In a recent research note, Suvannavejh upgraded the firm’s assumptions around EyePoint and raised the price target to $39 from $36. That new target implies roughly 226% upside from the stock’s current trading level, according to the note. Mizuho also increased its internal probability of success for EyePoint’s lead program to 75% from 70% following discussions with key opinion leaders and investors.
The catalyst driving the revised outlook is the expected top-line readout next month of the Phase 3 LUGANO study. LUGANO represents the first of two pivotal non-inferiority trials testing Duravyu, EyePoint’s tyrosine kinase inhibitor-based maintenance therapy for wet age-related macular degeneration. Mizuho characterizes Duravyu as positioned to be a best-in-class therapy in this indication.
On modeling, Mizuho assigns Duravyu a global peak 2040 risk-adjusted revenue of $1.4 billion, applying a 75% probability of success. The firm says that a positive LUGANO outcome could lead to a doubling of the stock, and that if probability-of-success assumptions were increased further to the 85-90% range, upside could exceed 300% on a discounted cash flow basis. Conversely, the analyst notes that a negative readout could drive the stock down toward roughly $3 per share, which he estimates would reflect a cash-per-share valuation.
Mizuho’s $39 price target rests on a discounted cash flow valuation using a 13% discount rate and a 2% terminal growth rate, as detailed in the research note.
Year-to-date performance metrics cited in the note show EyePoint’s stock down about 32% versus a 23% gain in the XBI biotech index. Intraday trading data included in the note referenced an uptick in EyePoint shares, while the broader XBI posted a smaller advance.
Separately, EyePoint announced that an independent safety committee reviewed its Phase 3 DURAVYU program and recommended that the trials continue without modification. The company also received new analyst coverage from Stifel, which initiated with a buy rating and a $40 price target.
Context and implications - Mizuho’s revision reflects both the proximity of a pivotal clinical readout and recent conversations with medical and investor contacts. The firm’s modeling highlights how outcomes from a single pivotal study can materially swing valuations in the small- and mid-cap biotech segment.
Market reaction - With the potential for a large move in either direction depending on the LUGANO results, EyePoint’s stock has been volatile year-to-date relative to the sector index.
What to watch next - Investors will focus on the top-line LUGANO data expected next month, the independent safety committee’s ongoing recommendations, and any additional analyst commentary that follows the readout.